Voya Investment Management LLC Sells 448,706 Shares of Danaher Corporation $DHR

Voya Investment Management LLC reduced its holdings in shares of Danaher Corporation (NYSE:DHR) by 28.8% in the third quarter, Holdings Channel reports. The institutional investor owned 1,107,994 shares of the conglomerate’s stock after selling 448,706 shares during the period. Voya Investment Management LLC’s holdings in Danaher were worth $219,390,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. YHB Investment Advisors Inc. increased its holdings in Danaher by 2.6% during the 3rd quarter. YHB Investment Advisors Inc. now owns 86,887 shares of the conglomerate’s stock worth $17,226,000 after purchasing an additional 2,161 shares in the last quarter. Agate Pass Investment Management LLC boosted its position in shares of Danaher by 1.9% during the third quarter. Agate Pass Investment Management LLC now owns 13,500 shares of the conglomerate’s stock valued at $2,677,000 after buying an additional 249 shares during the last quarter. Osprey Private Wealth LLC boosted its position in shares of Danaher by 40.4% during the third quarter. Osprey Private Wealth LLC now owns 15,375 shares of the conglomerate’s stock valued at $3,048,000 after buying an additional 4,425 shares during the last quarter. Peak Financial Advisors LLC grew its holdings in Danaher by 38.7% during the third quarter. Peak Financial Advisors LLC now owns 3,373 shares of the conglomerate’s stock worth $669,000 after buying an additional 942 shares in the last quarter. Finally, Dudley & Shanley Inc. raised its position in Danaher by 4.9% in the 3rd quarter. Dudley & Shanley Inc. now owns 114,941 shares of the conglomerate’s stock valued at $22,788,000 after buying an additional 5,389 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling

In related news, Director Teri List sold 3,298 shares of Danaher stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares in the company, valued at approximately $4,702,593. The trade was a 13.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 30,248 shares of company stock valued at $6,609,663. Company insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on DHR. KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a report on Thursday. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 price target (down from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Barclays increased their price objective on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Wells Fargo & Company boosted their target price on Danaher from $230.00 to $240.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Jefferies Financial Group increased their price target on Danaher from $245.00 to $255.00 and gave the company a “buy” rating in a research report on Wednesday. Twenty-one research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $248.25.

Danaher Stock Performance

NYSE:DHR opened at $224.43 on Friday. The company has a market capitalization of $158.53 billion, a P/E ratio of 46.28, a P/E/G ratio of 4.32 and a beta of 0.89. The business has a fifty day simple moving average of $219.93 and a two-hundred day simple moving average of $206.66. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the prior year, the company earned $1.71 EPS. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a $0.32 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s payout ratio is 26.39%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.